Charitable trust registration requires a specified-violation notice; settled cash deposits and related-party payments did not justify cancellation or ...
External development charges trigger TDS under section 194C, while disputed administrative payments require factual verification and fresh adjudicatio...
Section 270AA penalty immunity requires identified statutory defaults and a hearing before rejection; reassessment disclosure may constitute under-rep...
Section 80JJAA employee-cost deduction allowed for deployed staff but barred against transfer-pricing income enhancement, with pricing issues remanded...
Transfer-pricing methodology protects commercially genuine associated-enterprise payments, while pre-2016 secondary adjustments and related notional i...
Negative liens over operating assets can constitute international transactions requiring arm's-length pricing reflecting restricted borrowing and expa...
Cross-examination rights in Customs Broker revocation inquiries require witness examination; procedural denial may be cured through fresh adjudication...
Various issues related to allowability of expenses, deductions, transfer pricing adjustments, and other income tax matters for a pharmaceutical company. Key points are: Expenses incurred in providing freebies to doctors are disallowed u/s 37(1) retrospectively from 14-12-2009 as per MCI regulations and CBDT circular. Disallowance restricted to 5% of business advancement and sales promotion expenses, and entire doctor sponsorship expenses disallowed. Employee PF/ESI contribution disallowed for late deposits. Deductions u/ss 80-IC and 80-IE allowed for certain incomes like notice pay, scrap sale, service tax refund, miscellaneous income, export benefits, insurance claims, forex gains, cash discounts. Interest income eligible after excluding related expenses. Government biotechnology grant not connected to eligible units, hence disallowed. Administrative expenses allocated based on human resources instead of turnover. Leave encashment provision disallowed u/s 43B, allowed on actual payment. Weighted deduction u/s 35(2AB) allowed for certain R&D expenses like clinical trials, product registration, interest, labor charges, furniture, electrical equipment. Disallowance u/s 14A not added to book profits under 115JB. Transfer pricing adjustments: No adjustment for corporate guarantee fee already offere.
Various issues related to allowability of expenses, deductions, transfer pricing adjustments, and other income tax matters for a pharmaceutical company. Key points are: Expenses incurred in providing freebies to doctors are disallowed u/s 37(1) retrospectively from 14-12-2009 as per MCI regulations and CBDT circular. Disallowance restricted to 5% of business advancement and sales promotion expenses, and entire doctor sponsorship expenses disallowed. Employee PF/ESI contribution disallowed for late deposits. Deductions u/ss 80-IC and 80-IE allowed for certain incomes like notice pay, scrap sale, service tax refund, miscellaneous income, export benefits, insurance claims, forex gains, cash discounts. Interest income eligible after excluding related expenses. Government biotechnology grant not connected to eligible units, hence disallowed. Administrative expenses allocated based on human resources instead of turnover. Leave encashment provision disallowed u/s 43B, allowed on actual payment. Weighted deduction u/s 35(2AB) allowed for certain R&D expenses like clinical trials, product registration, interest, labor charges, furniture, electrical equipment. Disallowance u/s 14A not added to book profits under 115JB. Transfer pricing adjustments: No adjustment for corporate guarantee fee already offere.
Note: It is a system-generated summary and is for quick reference only.